Peter Hamley
Papers
2
Total Citations
99
H-Index
2
About
Peter Hamley is a pioneering researcher whose work bridges the frontiers of autophagy, cancer biology, and high-throughput drug discovery. His most impactful contribution is the landmark 2021 study demonstrating that IGF1 receptor inhibition amplifies the effects of cancer drugs through both autophagy-dependent and immune-mediated mechanisms. This breakthrough, which has already garnered 77 citations, provides a preclinically validated strategy for treating age-associated diseases by pharmacologically enhancing autophagy—a finding with profound implications for oncology and geroscience. Hamley’s earlier foundational work in medicinal chemistry, particularly his 2005 paper on high-throughput purification of single compounds and libraries (22 citations), established critical methodologies that enabled large-scale compound screening and purification. This technical expertise culminated in his leadership of a robotized high-content screen of 65,000 distinct compounds, showcasing his unique ability to combine automation, chemical biology, and mechanistic discovery. By integrating autophagy modulation with immune-based cancer therapies, Hamley has opened new therapeutic avenues, positioning him as a key figure in translational research where drug development meets cellular homeostasis.
Research Focus
Key Achievements
Top Papers
- 1
- 2High-Throughput Purification of Single Compounds and Libraries22 citations · 2005